As noted earlier, the FDA already has NurOwn on the
fast track and it will also get priority review when the package is complete. So Brainstorm can submit the NDA in pieces (which means less likelihood of surprise down the line), They've passed their interim safety analysis and will be releasing topline efficacy results next year.
This is all separate from "
Compassionate Use," a program for very small numbers of patients, and certainly not for a procedure like this.
As also noted earlier, the regimen now in trial hasn't been tried yet. It's the result of earlier trials and what was learned. That's not uncommon but underscores that it's something that needs to be tested. Some treatments previously tried for ALS did more harm than good overall, and it's not a cakewalk treatment.
To your concern, Ken, the issue with NurOwn won't be payor appetite or logistics (we do this sort of thing in certain cancers, for example) as much as waiting for the data to show if/how well/for whom it works. This trial won't tell us all that, since it's limited to rapid progressors but still with relatively high SVCs in order to increase its possible yield.
But hopefully it will work well enough in this group to merit approval, opening the door for other PALS as well, more data, more research to fine-tune the dosing and technique.
So while we await next year's results, anecdotal evidence is reason for hope, but no substitute for what P/CALS can do to help themselves/each other today and tomorrow.